Assertio Holdings Inc (ASRT)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$23.500.00%
Close 2026-06-17 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · ASRT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
As a result of Purchaser’s acceptance for payment of all Shares that were validly tendered and not validly withdrawn in accordance with the terms of the Offer, on June 16, 2026, a change of control of the Company occurred. As a result of the consummation of the Merger pursuant to Section 251(h) of the DGCL at the Effective Time, the Company became a wholly owned subsidiary of Parent. Parent and Purchaser have immediately available to them, through a variety of sources, including cash on hand…
In connection with the closing of the Merger, the Company (i) notified The Nasdaq Capital Market (“ Nasdaq ”) that the Merger was consummated and (ii) requested that Nasdaq (A) halt trading of and delist the Shares effective before the opening of trading on June 16, 2026, and (B) file with the SEC a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”).…
On June 16, 2026, in connection with the Merger (as defined below), the Company and U.S. Bank Trust Company, National Association, as trustee (the “ Trustee ”), entered into the First Supplemental Indenture, dated as of June 16, 2026 (the “ First Supplemental Indenture ”), to the Indenture, dated as of August 25, 2022, by and between the Company and the Trustee (the “ Original Indenture ” and, together with the First Supplemental Indenture, the “ Indenture ”), relating to the Company’s 6.50%…
The Offer and withdrawal rights expired as scheduled at one minute following 11:59 p.m., New York City time, on June 15, 2026 (such date and time, the “ Expiration Time ”). According to Equiniti Trust Company, LLC, the depositary for the Offer (the “ Depositary ”), 4,286,488 Shares were validly tendered and not validly withdrawn, representing approximately 66.32% of the issued and outstanding Shares as of the time Purchaser accepted such tendered Shares for payment (the “ Acceptance Time ”).…
Except as described in Item 2.01, pursuant to the Merger Agreement, each outstanding Share that was issued and outstanding immediately prior to the Effective Time, was automatically canceled and converted at the Effective Time into the right to receive the Merger Consideration. Accordingly, at the Effective Time, the holders of such Shares ceased to have any rights as stockholders of the Company, other than the right to receive the Merger Consideration.
Director: All previous directors and officers resigned as part of a merger, leading to new external hires.
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. The information set forth in the Introductory Note and
Other Events. On May 13, 2026, Assertio Holdings, Inc. (the “ Company ” or “ Assertio ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Zydus Worldwide DMCC, a limited liability company incorporated under the laws of the United Arab Emirates (“ Parent ”), Zara Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“ Purchaser ”) and, solely for purposes of Section 9.20 of the Merger Agreement, Zydus Pharmaceuticals (USA) Inc., a New Jers…
Termination of a Material Definitive Agreement. As previously disclosed, the Company entered into an Amended and Restated Agreement and Plan of Merger on May 1, 2026 (the “ Garda Merger Agreement ”) with Garda Therapeutics, Inc., a Delaware corporation (“ Garda ”) and Audi Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Garda. Following the Board’s determination, after consultation with its outside legal counsel and its financial advisors, that it had received a “Sup…
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On May 13, 2026, Assertio Holdings, Inc. (the “ Company ” or “ Assertio ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Zydus Worldwide DMCC, a limited liability company incorporated under the laws of the United Arab Emirates (“ Parent ”), Zara Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“ Purchaser ”) and, solely for purposes of Section 9.20 of the Mer…
The filing pertains to an amendment and restatement of the Company’s Amended and Restated 2014 Omnibus Incentive Plan.
Entry into a Material Definitive Agreement. Amended and Restated Agreement and Plan of Merger On May 1, 2026, Assertio Holdings, Inc. (the “ Company ” or “ Assertio ”) entered into an Amended and Restated Agreement and Plan of Merger (the “ Amended and Restated Merger Agreement ”) with Garda Therapeutics, Inc., a Delaware corporation (“ Parent ”), and Audi Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”), which amends and restates in its entiret…
Completion of Acquisition or Disposal of Assets. Sale of Products to Cosette Pharmaceuticals, Inc. As previously announced on April 8, 2026, Assertio Holdings, Inc. (the “ Company ”) and certain wholly-owned subsidiaries of the Company (collectively, the “ Sellers ”) entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with Cosette Pharmaceuticals, Inc., a Delaware corporation (“ Cosette ”). On April 8, 2026, the Company also completed the sale (the “ Asset Sale ”) of i…
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On April 8, 2026, Assertio Holdings, Inc. (the “ Company ” or “ Assertio ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Garda Therapeutics, Inc., a Delaware corporation (“ Parent ”), and Audi Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”). The Merger Agreement provides for, among other things, (i) the acquisition of the Company by Parent t…
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On April 8, 2026, Assertio Holdings, Inc. (the “ Company ” or “ Assertio ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Garda Therapeutics, Inc., a Delaware corporation (“ Parent ”), and Audi Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”). The Merger Agreement provides for, among other things, (i) the acquisition of the Company by Parent t…
of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Material Modification to Rights of Security Holders. On December 19, 2025, Assertio Holdings, Inc. (the “ Company ”) filed a Certificate of Amendment to its certificate of incorporation (the “ Certificate of Amendment ”) to implement a reverse stock split (the “ Reverse Split ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at a ratio of 1:15 (the “ Reverse Split Ratio ”). The Reverse Split was approved by the Company’s stockholders at this year’s annual m…
Chief Executive Officer and Director — Brendan P. O’Grady: Mr. O'Grady resigned as a member of the Board of Directors and former CEO after executing a waiver and release agreement.
President and Chief Operating Officer — Mr. Paul Schwichtenberg: Internal promotion of Mr. Paul Schwichtenberg to President and Chief Operating Officer.
of this Current Report on Form 8-K (“Form 8-K”) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the “SEC”) made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
CEO — Brendan O'Grady: Mr. O'Grady separated from service as CEO due to an 'Other Involuntary Termination.'
Entry into a Material Definitive Agreement. On October 7, 2025, Spectrum Pharmaceuticals, Inc. (“Spectrum”), a wholly owned subsidiary of Assertio Holdings, Inc. (the “Company”), and Hanmi Pharmaceutical Co. Ltd. (the “Supplier”) entered into an amendment and restatement (the “Amendment”) of the Supply Agreement dated February 28, 2018, as previously amended, which provides for the supply of ROLVEDON drug substance to Spectrum (the “Agreement”). Among other things, the Amendment establishes l…
of this Current Report on Form 8-K ("Form 8-K") shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the "SEC") made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
The filing pertains to an amendment and restatement of the Company’s stock incentive plan, not a management change.
of this Current Report on Form 8-K ("Form 8-K") shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the "SEC") made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.